Association of multidimensional comorbidities with survival, toxicity, and unplanned hospitalizations in older adults with metastatic colorectal cancer treated with chemotherapy.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cardiovascular Diseases
/ epidemiology
Colorectal Neoplasms
/ drug therapy
Comorbidity
Female
Hematologic Diseases
/ chemically induced
Hospitalization
/ statistics & numerical data
Humans
Liver Neoplasms
/ drug therapy
Lung Neoplasms
/ drug therapy
Male
Multiple Chronic Conditions
/ epidemiology
Neoplasm Metastasis
Otorhinolaryngologic Diseases
/ epidemiology
Proportional Hazards Models
Respiratory Tract Diseases
/ epidemiology
Retrospective Studies
Survival Rate
Colorectal cancer
Comorbidity
Geriatric oncology
Heat maps
Journal
Journal of geriatric oncology
ISSN: 1879-4076
Titre abrégé: J Geriatr Oncol
Pays: Netherlands
ID NLM: 101534770
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
09
08
2018
revised:
10
01
2019
accepted:
04
02
2019
pubmed:
16
2
2019
medline:
18
8
2020
entrez:
16
2
2019
Statut:
ppublish
Résumé
Studies of older patients with colorectal cancer(CRC) have found inconsistent results about the correlation of various comorbidities with overall survival(OS) and treatment tolerance. To refine our understanding, we evaluated this correlation using the Cumulative Illness Rating Scale-Geriatric(CIRS-G) and heat maps to identify subgroups with the highest impact. We retrospectively reviewed 153 patients aged 65 years and older with stage IV CRC undergoing chemotherapy. We calculated CIRS-G scores, and a Total Risk Score(TRS) derived from a previous heat map study. The association between CIRS-G scores/TRS and OS, unplanned hospitalizations, and chemotoxicity was examined by the Cox proportional hazards model. Median age was 71 years. Median MAX2 score of chemotherapies was 0.134(0.025-0.231). The most common comorbidities were vascular(79.8%), eye/ear/nose/throat(68%), and respiratory disease(52.4%). Median OS was 25.1 months(95% confidence interval: 21.2-27.6). In univariate analysis, ECOG PS ≥ 2(HR 1.86(1.1-3.17), p = 0.019), poorly differentiated histology(HR 2.03(1.27-3.25), p = 0.003), primary site(rectum vs colon)(HR 0.58 (0.34-0.98), p = 0.04), age at diagnosis(HR per 5y 1.20 (1.04-1.39), p = 0.012), and number of CIRS-G grade 4 comorbidities(HR 1.86 (1.1-3.17), p = 0.019) were associated with OS. In multivariate analysis, the number of CIRS-G grade 4 comorbidities lost significance, although it retained it in the subgroup of patients with colon cancer. Conversely, the TRS was associated with OS in patients with rectal cancer. No association of comorbidity with unplanned hospitalization or chemotoxicity was observed. In older adults with metastatic CRC, the number of CIRS-G grade 4 comorbidities was associated with worse OS but no specific CIRS-G category was independently associated with OS, unplanned hospitalization, or toxicities.
Sections du résumé
BACKGROUND
Studies of older patients with colorectal cancer(CRC) have found inconsistent results about the correlation of various comorbidities with overall survival(OS) and treatment tolerance. To refine our understanding, we evaluated this correlation using the Cumulative Illness Rating Scale-Geriatric(CIRS-G) and heat maps to identify subgroups with the highest impact.
METHODS
We retrospectively reviewed 153 patients aged 65 years and older with stage IV CRC undergoing chemotherapy. We calculated CIRS-G scores, and a Total Risk Score(TRS) derived from a previous heat map study. The association between CIRS-G scores/TRS and OS, unplanned hospitalizations, and chemotoxicity was examined by the Cox proportional hazards model.
RESULTS
Median age was 71 years. Median MAX2 score of chemotherapies was 0.134(0.025-0.231). The most common comorbidities were vascular(79.8%), eye/ear/nose/throat(68%), and respiratory disease(52.4%). Median OS was 25.1 months(95% confidence interval: 21.2-27.6). In univariate analysis, ECOG PS ≥ 2(HR 1.86(1.1-3.17), p = 0.019), poorly differentiated histology(HR 2.03(1.27-3.25), p = 0.003), primary site(rectum vs colon)(HR 0.58 (0.34-0.98), p = 0.04), age at diagnosis(HR per 5y 1.20 (1.04-1.39), p = 0.012), and number of CIRS-G grade 4 comorbidities(HR 1.86 (1.1-3.17), p = 0.019) were associated with OS. In multivariate analysis, the number of CIRS-G grade 4 comorbidities lost significance, although it retained it in the subgroup of patients with colon cancer. Conversely, the TRS was associated with OS in patients with rectal cancer. No association of comorbidity with unplanned hospitalization or chemotoxicity was observed.
CONCLUSIONS
In older adults with metastatic CRC, the number of CIRS-G grade 4 comorbidities was associated with worse OS but no specific CIRS-G category was independently associated with OS, unplanned hospitalization, or toxicities.
Identifiants
pubmed: 30765268
pii: S1879-4068(18)30298-4
doi: 10.1016/j.jgo.2019.02.003
pmc: PMC6689443
mid: NIHMS1522161
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
733-741Subventions
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.
Références
Hematol Oncol Clin North Am. 2000 Feb;14(1):1-16
pubmed: 10680068
Hematol Oncol Clin North Am. 2000 Feb;14(1):269-81
pubmed: 10680082
Eur J Cancer. 2000 Mar;36(4):453-71
pubmed: 10717521
Eur J Cancer. 2002 Jul;38(11):1466-73
pubmed: 12110492
Arch Otolaryngol Head Neck Surg. 2002 Oct;128(10):1172-9
pubmed: 12365889
Crit Rev Oncol Hematol. 2004 Jan;49(1):69-75
pubmed: 14734156
Psychiatry Res. 1992 Mar;41(3):237-48
pubmed: 1594710
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Br J Cancer. 2005 Nov 14;93(10):1098-105
pubmed: 16234816
Eur J Cancer. 2010 Aug;46(12):2225-34
pubmed: 20471248
Am J Epidemiol. 2010 Aug 1;172(3):299-308
pubmed: 20603278
Ann Oncol. 2011 Jan;22(1):118-26
pubmed: 20603436
Oncologist. 2011;16(3):378-87
pubmed: 21349949
J Clin Oncol. 2011 Sep 1;29(25):3457-65
pubmed: 21810685
Cancer. 2012 Jul 1;118(13):3377-86
pubmed: 22072065
Br J Cancer. 2012 Mar 27;106(7):1353-60
pubmed: 22353805
Br J Cancer. 2013 Oct 1;109(7):2005-13
pubmed: 24022185
Clin Epidemiol. 2013 Nov 01;5(Suppl 1):3-29
pubmed: 24227920
Clin Epidemiol. 2013 Nov 01;5(Suppl 1):65-74
pubmed: 24227924
Cancer. 2015 Sep 1;121(17):2984-92
pubmed: 26033177
J Gastrointest Oncol. 2015 Dec;6(6):605-12
pubmed: 26697191
J Geriatr Oncol. 2016 Mar;7(2):90-8
pubmed: 26739557
J Geriatr Oncol. 2017 Sep;8(5):336-342
pubmed: 28739160
Drugs Aging. 1994 Apr;4(4):313-24
pubmed: 8019054
J Clin Oncol. 1998 Apr;16(4):1582-7
pubmed: 9552069